Latest filings (excl ownership)
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7 May 24
8-K
Entry into a Material Definitive Agreement
7 May 24
8-K
BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately
3 May 24
8-K
Departure of Directors or Certain Officers
2 May 24
10-K
2023 FY
Annual report
16 Apr 24
NT 10-K
Notice of late annual filing
2 Apr 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
18 Mar 24
8-K
Entry into a Material Definitive Agreement
12 Mar 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
11 Mar 24
8-K
Departure of Directors or Certain Officers
28 Feb 24
8-K
Departure of Directors or Certain Officers
21 Feb 24
8-K
BioSig’s PURE EP™ Platform with New Near Field Tracking Algorithm Surpasses 100 Patient Cases
6 Feb 24
8-K/A
Cost Associated with Exit or Disposal Activities
2 Feb 24
8-K
Cost Associated with Exit or Disposal Activities
1 Feb 24
8-K
BioSig Announces Reverse Stock Split
31 Jan 24
8-K
BioSig Announces Cost Reductions to Improve its Financial Standing and Shifts its Core Strategy
30 Jan 24
D
$1.48 mm in equity / options / securities to be acquired, sold $1.48 mm, 7 investors
16 Jan 24
8-K
Entry into a Material Definitive Agreement
12 Jan 24
8-K
Other Events
8 Jan 24
S-3/A
Shelf registration (amended)
5 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
28 Dec 23
S-3
Shelf registration
28 Dec 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
22 Dec 23
8-K
Departure of Directors or Certain Officers
18 Dec 23
8-K
Regulation FD Disclosure
6 Dec 23
8-K
Departure of Directors or Certain Officers
5 Dec 23
DEF 14A
Definitive proxy
1 Dec 23
PRE 14A
Preliminary proxy
21 Nov 23
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
13 Nov 23
8-K
BioSig Announces $2.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
13 Nov 23
424B5
Prospectus supplement for primary offering
13 Nov 23
8-K
Amendments to Articles of Incorporation or Bylaws
8 Nov 23
8-K
BioSig Appoints Global MedTech Leader Fred Hrkac as New Executive VP
7 Nov 23
DEFA14A
Additional proxy soliciting materials
3 Nov 23
ARS
2022 FY
Annual report to shareholders
3 Nov 23
DEF 14A
Definitive proxy
3 Nov 23
8-K
Regulation FD Disclosure
2 Nov 23
8-K
Termination of a Material Definitive Agreement
2 Nov 23
8-K
BioSig Adds Five New Patent Awards to 100+ Total Patent Portfolio Covering Digital Signal Processing Technology and AI
1 Nov 23
Latest ownership filings
144
Notice of proposed sale of securities
11 Mar 24
4
Frederick Hrkac
4 Mar 24
SC 13G
ARMISTICE CAPITAL, LLC
14 Feb 24
4
Frederick Hrkac
4 Jan 24
4/A
John Sieckhaus
5 Dec 23
4/A
Gray Fleming
5 Dec 23
4
John Sieckhaus
4 Dec 23
4
Gray Fleming
4 Dec 23
4
KENNETH L LONDONER
4 Dec 23
4
IV David Weild
18 Aug 23
4
James L Klein
18 Aug 23
4
Frederick Hrkac
18 Aug 23
4
Patrick Joseph Gallagher
18 Aug 23
4
DONALD E FOLEY
18 Aug 23
4
James J Barry
18 Aug 23
4
KENNETH L LONDONER
13 Jun 23
4
KENNETH L LONDONER
12 Jun 23
4
KENNETH L LONDONER
9 Jun 23
4
John Sieckhaus
9 May 23
4
KENNETH L LONDONER
9 May 23
4
Gray Fleming
9 May 23
4
IV David Weild
21 Apr 23
4
James L Klein
21 Apr 23
4
Frederick Hrkac
21 Apr 23
4
Patrick Joseph Gallagher
21 Apr 23
4
DONALD E FOLEY
21 Apr 23
4
James J Barry
21 Apr 23
4/A
Frederick Hrkac
21 Apr 23
4
James J Barry
28 Feb 23
4
DONALD E FOLEY
28 Feb 23
4
Frederick Hrkac
28 Feb 23
4
Patrick Joseph Gallagher
28 Feb 23
4
James L Klein
28 Feb 23
4
IV David Weild
28 Feb 23
4
STEVEN J BUHALY
17 Feb 23
4
STEVEN J BUHALY
8 Feb 23
3
STEVEN J BUHALY
7 Feb 23
4
IV David Weild
22 Nov 22
4
James L Klein
22 Nov 22
4
Frederick Hrkac
22 Nov 22